<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Flurbiprofen (FL) (2-(2-fluoro-4-biphenyl) propionic acid) is a cyclooxygenase (COX-1 and 2) inhibitor that blocks the synthesis of prostaglandin E2 and is reported to have analgesic and anti-inflammatory effects [
 <xref rid="B1-pharmaceutics-10-00247" ref-type="bibr" class="xref">1</xref>]. Its clinical efficacy has been known as symptom and pain relief in several inflammation diseases, such as rheumatoid arthritis, osteoarthritis, arthralgia, and ankylosing spondylitis [
 <xref rid="B2-pharmaceutics-10-00247" ref-type="bibr" class="xref">2</xref>]. This drug is classified to BCS class II and exhibits low aqueous solubility (5–10 μg/mL) [
 <xref rid="B3-pharmaceutics-10-00247" ref-type="bibr" class="xref">3</xref>,
 <xref rid="B4-pharmaceutics-10-00247" ref-type="bibr" class="xref">4</xref>]. Solubilization formulation influences the absorption and oral bioavailability of FL, since FL is practically water-insoluble [
 <xref rid="B5-pharmaceutics-10-00247" ref-type="bibr" class="xref">5</xref>]. Various formulations, such as solid lipid nanoparticles (SLNs), β-cyclodextrin complex, nanosuspensions, and a self-microemulsifying drug delivery system (SMEDDS), have been applied to improve bioavailability by increasing the solubility and dissolution rate of FL [
 <xref rid="B6-pharmaceutics-10-00247" ref-type="bibr" class="xref">6</xref>,
 <xref rid="B7-pharmaceutics-10-00247" ref-type="bibr" class="xref">7</xref>,
 <xref rid="B8-pharmaceutics-10-00247" ref-type="bibr" class="xref">8</xref>,
 <xref rid="B9-pharmaceutics-10-00247" ref-type="bibr" class="xref">9</xref>].
</p>
